International Journal of Radiation Oncology*Biology*Physics
Volume 39, Issue 2, 1 September 1997, Pages 505-519
Physic contributionConformal episcleral plaque therapy
References (21)
- et al.
An interactive treatment planning system for ophthalmic plaque radiotherapy
Int. J. Radia. Oncol. Biol. Phys.
(1990) - et al.
The treatment of primary intraocular malignancy
Int. J. Radiat. Oncol. Biol. Phys.
(1988) - et al.
Dosimetric calculations and measurements of gold plaque ophthalmic irradiators using Iridium-192 and Iodine-125 Seeds
Int. J. Radiat. Oncol. Biol. Phys.
(1988) - et al.
Measurement of dose rate from exposure-calibrated 125I seeds
Int. J. Radiat. Oncol. Biol. Phys.
(1990) - et al.
Radiotherapy of choroidal melanoma with iodine-125
Ophthalmology
(1980) - et al.
Episcleral plaque radiotherapy in the treatment of uveal melanomas
Int. J. Radiat. Oncol. Biol. Phys.
(1992) - et al.
Episcleral plaque thermoradiotherapy in patients with choroidal melanoma
Int. J. Radiat. Oncol. Biol. Phys.
(1992) - et al.
Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings
Ophthalmology
(1989) - et al.
Optimization of 125I ophthalmic plaque brachytherapy
Med. Phys.
(1990) - et al.
Choroidal melamoma: I-125 plaque therapy
Radiology
(1988)
There are more references available in the full text version of this article.
Cited by (70)
Dose evaluation of 142Pr radioisotope by Monte Carlo method in eye brachytherapy
2020, Radiation Physics and ChemistryEvidence for Dose De-escalation in Brachytherapy for Choroidal Melanoma
2018, Advances in Ophthalmology and OptometryEvaluating Retinal Sequelae of Radioactive Episcleral Plaque Brachytherapy for Medium-Sized Choroidal Melanomas Using Optical Coherence Tomography Angiography
2017, Advances in Ophthalmology and OptometryCitation Excerpt :In an era of personalized medicine, plaque brachytherapy has similarly been adapted to an individual’s tumor characteristics to deliver more tailored radiation therapy. Gold-backed plaques and collimation were designed to reduce the scleral dose, deliver a more homogenous dose to the tumor, and attenuate radiation delivered to essential ocular structures, such as the macula and optic nerve [15]. However, a significant portion of dosimetry is determined by the location of the tumor, which is clearly not modifiable.
Copyright © 1997 Published by Elsevier Inc.